Concurrent SOS1 and MEK suppression inhibits signaling and growth of NF1-null melanoma.

Autor: Marasco M; Molecular Pharmacology Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA., Kumar D; Molecular Pharmacology Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA., Seale T; Department of Oncology, Cancer Genetics and Epigenetics Program, Johns Hopkins University School of Medicine, Baltimore, MD, USA., Borrego SG; Department of Oncology, Cancer Genetics and Epigenetics Program, Johns Hopkins University School of Medicine, Baltimore, MD, USA., Kaplun E; Molecular Pharmacology Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA., Aricescu I; Gerstner Sloan Kettering Graduate School of Biomedical Sciences, New York, NY, USA., Cole S; Department of Oncology, Cancer Genetics and Epigenetics Program, Johns Hopkins University School of Medicine, Baltimore, MD, USA., Qeriqi B; Antitumor Assessment Core Facility, Memorial Sloan Kettering Cancer Center, New York, NY, USA., Qiu J; Antitumor Assessment Core Facility, Memorial Sloan Kettering Cancer Center, New York, NY, USA., Chen X; Antitumor Assessment Core Facility, Memorial Sloan Kettering Cancer Center, New York, NY, USA., Bahr A; Antitumor Assessment Core Facility, Memorial Sloan Kettering Cancer Center, New York, NY, USA., Fidele D; Antitumor Assessment Core Facility, Memorial Sloan Kettering Cancer Center, New York, NY, USA., Hofmann MH; Boehringer Ingelheim RCV GmbH & Co KG, Vienna, Austria., Gerlach D; Boehringer Ingelheim RCV GmbH & Co KG, Vienna, Austria., Savarese F; Boehringer Ingelheim RCV GmbH & Co KG, Vienna, Austria., Merghoub T; Sandra and Edward Meyer Cancer Center at Weill Cornell Medicine, New York, NY, USA., Wolchok JD; Sandra and Edward Meyer Cancer Center at Weill Cornell Medicine, New York, NY, USA., Yao Z; Mechanistic Biology, Loxo Oncology at Lilly, New York, NY, USA., de Stanchina E; Antitumor Assessment Core Facility, Memorial Sloan Kettering Cancer Center, New York, NY, USA., Solit D; Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA; Kravis Center for Molecular Oncology, Memorial Sloan Kettering Cancer Center, New York, NY, USA., Misale S; Department of Oncology, Cancer Genetics and Epigenetics Program, Johns Hopkins University School of Medicine, Baltimore, MD, USA. Electronic address: smisale1@jh.edu., Rosen N; Molecular Pharmacology Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA; Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA. Electronic address: rosenn@mskcc.org.

Publikováno v: Cell reports. Medicine [Cell Rep Med] 2024 Nov 19; Vol. 5 (11), pp. 101818. Date of Electronic Publication: 2024 Nov 01.

Tumefactive Primary Central Nervous System Vasculitis: Dynamic Susceptibility Contrast Perfusion-Weighted Magnetic Resonance Imaging Findings With Histological Correlation.

Autor: Muccio CF; Unit of Neuroradiology, Department of Neurosciences, 'San Pio' Hospital, Benevento, Italy., Di Lorenzo L; UO Riabilitazione, CMR SpA, Sant'Agata dei Goti, Neuromed network Pozzilli, Italy., Lepore G; Unit of Pathology, 'San Pio' Hospital, Benevento, Italy., Savarese F; Unit of Neuroradiology, Department of Neurosciences, 'San Pio' Hospital, Benevento, Italy., Schipani S; Unit of Neuroradiology, Department of Neurosciences, 'San Pio' Hospital, Benevento, Italy., Chiarotti I; Department of Neurological and Motor Sciences, Azienda Ospedaliero-Universitaria Senese, Policlinico 'Santa Maria alle Scotte', Siena, Italy., Cerase A; Department of Neurological and Motor Sciences, Azienda Ospedaliero-Universitaria Senese, Policlinico 'Santa Maria alle Scotte', Siena, Italy.

Publikováno v: La Clinica terapeutica [Clin Ter] 2024 Mar-Apr; Vol. 175 (2), pp. 112-117.

Fragment Optimization of Reversible Binding to the Switch II Pocket on KRAS Leads to a Potent, In Vivo Active KRAS ^G12C Inhibitor.

Autor: Bröker J; Boehringer Ingelheim RCV GmbH & Co. KG, Dr. Boehringer Gasse 5-11, A-1121 Vienna, Austria., Waterson AG; Department of Biochemistry, Vanderbilt University School of Medicine, 2215 Garland Avenue, 607 Light Hall, Nashville, Tennessee 37232-0146, United States., Smethurst C; Boehringer Ingelheim RCV GmbH & Co. KG, Dr. Boehringer Gasse 5-11, A-1121 Vienna, Austria., Kessler D; Boehringer Ingelheim RCV GmbH & Co. KG, Dr. Boehringer Gasse 5-11, A-1121 Vienna, Austria., Böttcher J; Boehringer Ingelheim RCV GmbH & Co. KG, Dr. Boehringer Gasse 5-11, A-1121 Vienna, Austria., Mayer M; Boehringer Ingelheim RCV GmbH & Co. KG, Dr. Boehringer Gasse 5-11, A-1121 Vienna, Austria., Gmaschitz G; Boehringer Ingelheim RCV GmbH & Co. KG, Dr. Boehringer Gasse 5-11, A-1121 Vienna, Austria., Phan J; Department of Biochemistry, Vanderbilt University School of Medicine, 2215 Garland Avenue, 607 Light Hall, Nashville, Tennessee 37232-0146, United States., Little A; Department of Biochemistry, Vanderbilt University School of Medicine, 2215 Garland Avenue, 607 Light Hall, Nashville, Tennessee 37232-0146, United States., Abbott JR; Department of Biochemistry, Vanderbilt University School of Medicine, 2215 Garland Avenue, 607 Light Hall, Nashville, Tennessee 37232-0146, United States., Sun Q; Department of Biochemistry, Vanderbilt University School of Medicine, 2215 Garland Avenue, 607 Light Hall, Nashville, Tennessee 37232-0146, United States., Gmachl M; Boehringer Ingelheim RCV GmbH & Co. KG, Dr. Boehringer Gasse 5-11, A-1121 Vienna, Austria., Rudolph D; Boehringer Ingelheim RCV GmbH & Co. KG, Dr. Boehringer Gasse 5-11, A-1121 Vienna, Austria., Arnhof H; Boehringer Ingelheim RCV GmbH & Co. KG, Dr. Boehringer Gasse 5-11, A-1121 Vienna, Austria., Rumpel K; Boehringer Ingelheim RCV GmbH & Co. KG, Dr. Boehringer Gasse 5-11, A-1121 Vienna, Austria., Savarese F; Boehringer Ingelheim RCV GmbH & Co. KG, Dr. Boehringer Gasse 5-11, A-1121 Vienna, Austria., Gerstberger T; Boehringer Ingelheim RCV GmbH & Co. KG, Dr. Boehringer Gasse 5-11, A-1121 Vienna, Austria., Mischerikow N; Boehringer Ingelheim RCV GmbH & Co. KG, Dr. Boehringer Gasse 5-11, A-1121 Vienna, Austria., Treu M; Boehringer Ingelheim RCV GmbH & Co. KG, Dr. Boehringer Gasse 5-11, A-1121 Vienna, Austria., Herdeis L; Boehringer Ingelheim RCV GmbH & Co. KG, Dr. Boehringer Gasse 5-11, A-1121 Vienna, Austria., Wunberg T; Boehringer Ingelheim RCV GmbH & Co. KG, Dr. Boehringer Gasse 5-11, A-1121 Vienna, Austria., Gollner A; Boehringer Ingelheim RCV GmbH & Co. KG, Dr. Boehringer Gasse 5-11, A-1121 Vienna, Austria., Weinstabl H; Boehringer Ingelheim RCV GmbH & Co. KG, Dr. Boehringer Gasse 5-11, A-1121 Vienna, Austria., Mantoulidis A; Boehringer Ingelheim RCV GmbH & Co. KG, Dr. Boehringer Gasse 5-11, A-1121 Vienna, Austria., Krämer O; Boehringer Ingelheim RCV GmbH & Co. KG, Dr. Boehringer Gasse 5-11, A-1121 Vienna, Austria., McConnell DB; Boehringer Ingelheim RCV GmbH & Co. KG, Dr. Boehringer Gasse 5-11, A-1121 Vienna, Austria., W Fesik S; Department of Biochemistry, Vanderbilt University School of Medicine, 2215 Garland Avenue, 607 Light Hall, Nashville, Tennessee 37232-0146, United States.

Publikováno v: Journal of medicinal chemistry [J Med Chem] 2022 Nov 10; Vol. 65 (21), pp. 14614-14629. Date of Electronic Publication: 2022 Oct 27.

Surgical CPT Coding Discrepancies: Analysis of Surgeons and Employed Coders.

Autor: Glauser G; University of Pennsylvania, Philadelphia, PA., Sharma N, Beatson N, Dimentberg R, Savarese F, Gagliardi M, Grady MS, Malhotra NR

Publikováno v: American journal of medical quality : the official journal of the American College of Medical Quality [Am J Med Qual] 2021 Jul-Aug 01; Vol. 36 (4), pp. 263-269.

Clinical Advances and Challenges in Targeting KRAS Mutations in Non-Small Cell Lung Cancer.

Autor: Dekker, Simone E.^1,2 (AUTHOR) dekker@uw.edu, Deng, Lei^1,2 (AUTHOR) ldeng1@fredhutch.org

Publikováno v: Cancers. Nov2024, Vol. 16 Issue 22, p3885. 12p.